-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) Largest Shareholder, CEO Min Hua Fan Sees Holdings Value Fall by 6.7% Following Recent Drop
Hainan Poly Pharm. Co., Ltd's (SZSE:300630) Largest Shareholder, CEO Min Hua Fan Sees Holdings Value Fall by 6.7% Following Recent Drop
To get a sense of who is truly in control of Hainan Poly Pharm. Co., Ltd (SZSE:300630), it is important to understand the ownership structure of the business. With 42% stake, individual insiders possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
And following last week's 6.7% decline in share price, insiders suffered the most losses.
Let's delve deeper into each type of owner of Hainan Poly Pharm, beginning with the chart below.
Check out our latest analysis for Hainan Poly Pharm
SZSE:300630 Ownership Breakdown September 20th 2022What Does The Institutional Ownership Tell Us About Hainan Poly Pharm?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Hainan Poly Pharm. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Hainan Poly Pharm's earnings history below. Of course, the future is what really matters.
SZSE:300630 Earnings and Revenue Growth September 20th 2022Hainan Poly Pharm is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is the CEO Min Hua Fan with 41% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 1.4%, of the shares outstanding, respectively.
Our research also brought to light the fact that roughly 51% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Hainan Poly Pharm
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems insiders own a significant proportion of Hainan Poly Pharm. Co., Ltd. It is very interesting to see that insiders have a meaningful CN¥4.5b stake in this CN¥11b business. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
General Public Ownership
The general public-- including retail investors -- own 34% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Hainan Poly Pharm you should be aware of, and 2 of them don't sit too well with us.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看谁才是海南保利医药的真正掌控者。对于上海证券交易所股份有限公司(深交所股票代码:300630)而言,了解企业的所有权结构非常重要。个人内部人士持有该公司42%的股份,拥有该公司的最大股份。换句话说,该集团面临着最大的上行潜力(或下行风险)。
继上周股价下跌6.7%之后,内部人士遭受的损失最大。
让我们从下面的图表开始,更深入地研究海南保利医药的每一种类型的所有者。
查看我们对海南保利医药的最新分析
深交所:300630所有权明细2022年9月20日关于海南保利医药,机构持股告诉了我们什么?
机构通常在向自己的投资者报告时,以基准来衡量自己,因此一旦一只股票被纳入主要指数,它们往往会对这只股票变得更加热情。我们预计,大多数公司都会有一些机构登记在册,特别是在它们正在增长的情况下。
如你所见,机构投资者在海南保利医药持有相当多的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。如果多家机构同时改变对一只股票的看法,你可能会看到股价迅速下跌。因此,值得关注的是海南保利医药的盈利历史。当然,未来才是真正重要的。
深交所:2022年9月20日收益和收入增长300630海南保利医药不为对冲基金所有。从我们的数据可以看出,第一大股东是持有41%流通股的首席执行官范民华。与此同时,第二大和第三大股东分别持有7.1%和1.4%的流通股。
我们的研究还揭示了这样一个事实,即公司约51%的股份由前4名股东控制,这表明这些所有者对业务具有重大影响。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。分析师对该股的报道不多,但也不多。因此,它有获得更多报道的空间。
海南保利医药的内部人所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
内部人士似乎拥有海南保利医药相当大的比例。非常有趣的是,看到内部人士在这笔CN元11亿元的业务中持有有意义的CN元45亿股份。大多数人会高兴地看到董事会与他们一起投资。你可能希望访问这张显示内部人士最近交易的免费图表。
一般公有制
包括散户投资者在内的普通公众持有该公司34%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。一个恰当的例子:我们发现了海南保利医药的3个警示标志你应该知道,他们中的两个和我们坐在一起不太好。
最终未来是最重要的。您可以访问此免费分析师对该公司的预测报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧